Oki S

ORCID: 0000-0002-4767-3259 · 4 papers in corpus
case-report 2025
A case of primary ovarian clear cell carcinoma with ETV6::NTRK3 fusion
International cancer conference journal ·doi:10.1007/s13691-025-00795-6

We report the first documented case of primary ovarian clear cell carcinoma harboring an ETV6::NTRK3 fusion gene. A 49-year-old woman presented with a rapidly growing ovarian cyst that was diagnosed as stage IC1 clear cell carcinoma followi…

lab-animal 2022
Regulome-based characterization of drug activity across the human diseasome
NPJ systems biology and applications ·doi:10.1038/s41540-022-00255-4

Drugs are expected to recover the cell system away from the impaired state to normalcy through disease treatment. However, the understanding of gene regulatory machinery underlying drug activity or disease pathogenesis is far from complete.…

lab-animal 2020
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells
Oncology letters ·doi:10.3892/ol.2020.12014

Previous studies have suggested that histone methylation can modulate carcinogenesis and cancer progression. For instance, the histone methyltransferase SET and MYND domain containing 2 (SMYD2) is overexpressed in several types of cancer ti…

lab-animal 2019
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation
BMC cancer ·doi:10.1186/s12885-019-5638-9

BACKGROUND: Wolf-Hirschhorn syndrome candidate gene-1 (WHSC1), a histone methyltransferase, has been found to be upregulated and its expression to be correlated with expression of enhancer of zeste homolog 2 (EZH2) in several cancers. In th…